Skip to content

Finance and markets

Page 49



APRA is tightening its grip on high-risk borrowers as investor lending surges and the big banks begin edging away from the most highly geared loans.




















Blackbird’s valuation adjustments for Culture Amp and SafetyCulture show how shifting markets shape venture values, and why write-downs aren’t always bad news.











We have world-class research and clinical trial strength, but risk aversion and limited capital are holding us back in biotech. Unlocking our potential requires bold investment.











Next page